|
Feb 17
|
Why Bristol-Myers Squibb (BMY) Is Among the Best Drug Stocks to Buy Now
|
|
Feb 16
|
New Five-Year Sotyktu (deucravacitinib) Data Show Consistent Safety and Durable Response Rates in Moderate-to-Severe Plaque Psoriasis
|
|
Feb 14
|
BioArctic AB (BRCTF) Q4 2024 Earnings Call Highlights: Strategic Partnerships and Profitability ...
|
|
Feb 13
|
Bristol Myers Squibb Provides Update on Phase 3 RELATIVITY-098 Trial
|
|
Feb 12
|
Bristol-Myers Squibb Company (BMY) – Jim Cramer: “No, No, You Don’t Hold”
|
|
Feb 12
|
Shareholders in Bristol-Myers Squibb (NYSE:BMY) have lost 7.2%, as stock drops 5.4% this past week
|
|
Feb 11
|
BMY Down 7% Post Q4 Earnings: Should You Buy, Sell or Hold the Stock?
|
|
Feb 11
|
Jim Cramer on Bristol-Myers (BMY): Cobenfy’s Success vs. Patent Headwinds
|
|
Feb 11
|
BMS’ Phase II trial of CAR T cell therapy meets primary endpoint
|
|
Feb 11
|
The Magnificent 7 Are So Last Year. Cash Cows Are the New Kings.
|
|
Feb 10
|
Bristol Myers Squibb Company (BMY) Is a Trending Stock: Facts to Know Before Betting on It
|
|
Feb 10
|
Royalty Pharma Earnings: What To Look For From RPRX
|
|
Feb 10
|
Bristol Myers Squibb Announces Positive Topline Results for Breyanzi® (lisocabtagene maraleucel) in Adult Patients with Relapsed or Refractory Marginal Zone Lymphoma
|
|
Jan 4
|
3 High-Yield Dividend Stocks to Buy Now and Hold at Least a Decade
|
|
Jan 3
|
Bristol Myers Squibb to Present at J.P. Morgan’s 43rd Annual Healthcare Conference
|
|
Jan 3
|
Update: Market Chatter: Drug Companies to Raise Prices on 250 Branded Drugs in 2025
|
|
Jan 2
|
Bristol-Myers Squibb's (NYSE:BMY) investors will be pleased with their 2.4% return over the last five years
|
|
Dec 31
|
Corcept Submits Application for Another Cushing's Syndrome Drug
|
|
Dec 31
|
Is Bristol-Myers Squibb Company (BMY) Among the Best Pharma Dividend Stocks to Buy In 2024?
|
|
Dec 30
|
Is Bristol-Myers Squibb Co. (BMY) the Best Stock for 10 Years?
|